Tenet Healthcare
THC
$260.57
+0.28%
Tenet Healthcare Corporation is a Dallas-based healthcare services organization that operates 50 acute and specialty hospitals and hundreds of ambulatory surgery centers and outpatient facilities, primarily concentrated in the southern United States, alongside its Conifer revenue cycle management segment. As one of the largest investor-owned hospital operators in the country, Tenet has increasingly repositioned itself as a diversified care delivery platform, with its high-margin Ambulatory Care segment (approximately $1.39 billion in quarterly revenue) complementing the larger Hospital Operations business (roughly $4.24 billion). The current investor narrative centers on the company's aggressive capital-return strategy, including an expanded share buyback program funded by robust free cash flow, as well as strong earnings growth and raised full-year guidance that have driven significant multiple expansion. Management has also been executing a deliberate portfolio transformation, divesting non-core assets and reinvesting in ambulatory surgery expansion, which analysts view as a margin-accretive pivot. However, the stock has faced periodic pressure from unfavorable patient insurance mix and soft revenue relative to earnings beats, highlighting persistent industry headwinds around payer dynamics and admission mix.…
THC
Tenet Healthcare
$260.57
Related headlines
Investment Opinion: Should I buy THC Today?
Based on the synthesized data, Tenet Healthcare earns a Buy rating. The core thesis is that the company is undervalued relative to its cash generation and growth prospects, with a forward PE of 12.26x and a price-to-free-cash-flow of 5.06x, while analysts' average target price of $284.64 implies 10.1% upside. The consensus recommendation is 'buy' with a mean of 1.57, reflecting strong institutional support.
Supporting evidence includes: 1) Revenue growth of 6.77% year-over-year in Q2 2026, with a consistent upward trajectory; 2) Net margin expansion to 14.68% from 5.46% a year ago, driven by operational efficiency and mix shift; 3) Robust free cash flow of $3.023 billion TTM, funding aggressive buybacks ($1.042 billion in Q2 2026); and 4) Attractive valuation multiples (EV/EBITDA of 6.29x) compared to the healthcare facilities industry. The company's ROE of 33.34% further highlights efficient capital deployment.
Key risks that could invalidate the thesis include: 1) High leverage (debt-to-equity of 3.12) and potential interest rate increases; 2) Payer mix headwinds that led to a Q1 2026 revenue miss; and 3) Decelerating momentum, with the stock up only 3.48% in the past month. The rating would upgrade to a Strong Buy if the stock breaks above its 52-week high of $283.05 with sustained volume, or downgrade to Hold if revenue growth falls below 5% or if margins contract. Relative to its history, the stock is undervalued on a PS basis (0.84x vs. historical range of 1.02x-3.38x), but the premium PB ratio warrants caution.
Sign up to view all
THC 12-Month Price Forecast
Tenet Healthcare presents a compelling investment opportunity, trading at low multiples despite strong earnings growth and cash flow generation. The company's strategic shift toward higher-margin ambulatory services and aggressive share buybacks are key drivers. However, high leverage and recent momentum deceleration warrant caution. The stock is likely to outperform over the next 12 months, but volatility may persist. An upgrade to high confidence would require sustained revenue acceleration and margin expansion, while a downgrade would occur if payer mix headwinds intensify or if free cash flow declines significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $285.32 and implied upside of +9.5% versus the current price.
Average Target
$285.32
0 analysts
Implied Upside
+9.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$260 - $315
Analyst target range
Tenet Healthcare is covered by 22 analysts, with a consensus recommendation of "buy" and a recommendation mean of 1.57 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating a solidly bullish consensus. The average target price of $284.64 implies approximately 10.1% upside from the current price of $258.62, suggesting analysts see meaningful but not explosive appreciation potential. The institutional ratings data shows a consistent pattern of bullish calls, with recent actions from Leerink Partners (Outperform), Wells Fargo (Overweight), Truist Securities (Buy), Guggenheim (Buy), UBS (Buy), Morgan Stanley (Overweight), TD Cowen (Buy), RBC Capital (Outperform), and Barclays (Overweight) — all maintained at bullish ratings, with only Baird maintaining a Neutral stance. This broad-based analyst support, with no downgrades in the recent ratings history, signals strong conviction in the company's strategic direction.
The target price range spans from a low of $260.00 to a high of $315.00, a spread of $55.00 or approximately 21% of the low target, indicating moderate dispersion in analyst expectations. The low target of $260.00 is essentially at the current stock price, implying that even the most conservative analyst sees the stock as fairly valued with no downside — a notably bullish signal. The high target of $315.00 would represent a 21.8% gain from current levels and likely assumes successful execution of the ambulatory expansion strategy, continued multiple expansion as the market recognizes the company's cash-generation capabilities, and further accretion from the buyback program. The estimated EPS average of $28.72 for the forward period, combined with estimated revenue of $24.09 billion, suggests analysts expect continued top-line growth and margin expansion. The tight clustering of analyst targets above the current price, combined with the absence of any sell ratings, paints a picture of a stock with strong institutional support and limited perceived downside risk, though the recent 1-month underperformance relative to the broader market may indicate that near-term catalysts have already been priced in.
Bulls vs Bears: THC Investment Factors
The bullish case for Tenet Healthcare is currently stronger, supported by robust earnings growth, margin expansion, and a compelling valuation with low multiples. The company's aggressive share buybacks and strong free cash flow generation further bolster the investment thesis. However, the bear case highlights significant leverage, recent momentum deceleration, and potential payer mix headwinds that could pressure future results. The most critical tension is whether Tenet can sustain its margin expansion and cash flow generation amid industry headwinds and high debt levels; resolution of this will determine the stock's trajectory.
Bullish
- Strong Earnings Growth and Margin Expansion: Q2 2026 net income surged to $826 million, a 187% increase from $288 million in Q2 2025, driving net margin to 14.68% from 5.46%. This dramatic profitability improvement reflects successful cost management and a favorable shift toward higher-margin ambulatory services.
- Attractive Valuation with Low Multiples: The stock trades at a trailing PE of 12.73x and forward PE of 12.26x, with an EV/EBITDA of 6.29x and price-to-free-cash-flow of 5.06x. These multiples are significantly below the broader market and historical averages, suggesting undervaluation relative to cash generation.
- Robust Free Cash Flow and Capital Returns: Tenet generated $3.023 billion in trailing twelve-month free cash flow and repurchased $1.042 billion in stock during Q2 2026 alone. This aggressive buyback program, funded entirely from operating cash flow, demonstrates management's confidence and enhances shareholder value.
- Consistent Revenue Growth and Raised Guidance: Revenue grew 6.77% year-over-year to $5.628 billion in Q2 2026, with a steady upward trend over the past six quarters. Management raised full-year guidance, and analysts project continued growth with estimated revenue of $24.09 billion.
Bearish
- High Leverage and Debt Burden: The debt-to-equity ratio of 3.12 and total debt-to-capitalization of 73.99% reflect significant leverage, which increases financial risk, especially in a rising interest rate environment. Interest expense of $204 million per quarter consumes a notable portion of operating income.
- Recent Momentum Deceleration: The stock has gained only 3.48% over the past month, underperforming the S&P 500 by 0.56 percentage points, a sharp slowdown from the 26.95% gain over three months. This deceleration suggests near-term catalysts may be priced in and momentum is waning.
- Payer Mix Headwinds and Revenue Misses: In Q1 2026, revenue fell short of expectations due to unfavorable patient insurance mix, highlighting persistent industry headwinds. This issue could recur and pressure margins if payer dynamics worsen.
- Premium Price-to-Book Ratio: The price-to-book ratio of 4.25x is elevated, reflecting thin tangible book value due to years of leverage and buybacks. This premium may not be sustainable if earnings growth slows or if the company faces financial distress.
THC Technical Analysis
Tenet Healthcare is in a powerful sustained uptrend, with the stock up 27.16% over the past year and 37.44% over six months, decisively outperforming the S&P 500's 15.01% and 17.35% respective gains. At a current price of $258.62, the stock is trading at approximately 80.6% of its 52-week range (low of $157.58 to high of $283.05), positioning it in the upper quartile of its annual band but still about 8.6% below its peak. This positioning suggests the stock retains upside momentum without being fully overextended at the highs, though the proximity to resistance warrants caution for momentum-chasing entries. The 1-year relative strength of +12.15% versus SPY confirms persistent alpha generation, though the stock's beta of 1.23 implies roughly 23% more volatility than the broad market, which is important for position sizing.
Short-term momentum has decelerated meaningfully, with the 1-month change of just +3.48% representing a sharp slowdown from the 3-month gain of +26.95% and the 6-month advance of +37.44%. This deceleration is corroborated by the 1-month relative strength of -0.56% versus SPY, meaning the stock has actually slightly underperformed the market over the past month despite its strong longer-term trajectory. The divergence between the robust 1-year trend (+27.16%) and the tepid 1-month performance (+3.48%) suggests a consolidation phase or temporary digestion of the massive July-August rally, when the stock surged from roughly $195 on July 23 to $262 by July 28 — a single-week gain of over 34% that likely reflected a major positive catalyst. Since peaking at $283.05, the stock has pulled back and traded in a $250-$270 range through September, indicating a healthy consolidation rather than a trend reversal.
Key technical support is anchored at the 52-week low of $157.58, with a more immediate support zone around $250, where the stock has found buyers multiple times in September (closing at $249.54 on September 24 and $253.97 on October 1). Resistance is defined by the 52-week high of $283.05, and a decisive breakout above this level would signal a resumption of the primary uptrend and likely open the door to new all-time highs. Conversely, a breakdown below $250 would suggest a deeper mean-reversion toward the $230-$240 area, where the stock consolidated in late July. With a beta of 1.23 and a maximum drawdown of -34.08% over the past year, investors should recognize that this stock can experience sharp corrections, and the current low short ratio of 2.75 suggests no significant bearish positioning that could fuel a short squeeze.
Beta
1.20
1.20x market volatility
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$158-$283
Price range past year
Annual Return
+30.0%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | +1.0% |
| 3m | +27.6% | +2.5% |
| 6m | +33.5% | +13.9% |
| 1y | +30.0% | +15.0% |
| ytd | +30.6% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Tenet's revenue trajectory remains solidly positive, with Q2 2026 revenue of $5.628 billion representing 6.77% year-over-year growth from $5.271 billion in Q2 2025. The multi-quarter trend shows consistent sequential expansion: revenue rose from $5.223 billion in Q1 2025 to $5.271 billion in Q2 2025, $5.289 billion in Q3 2025, $5.527 billion in Q4 2025, $5.368 billion in Q1 2026, and $5.628 billion in Q2 2026, reflecting a generally upward slope with minor seasonal fluctuations. The Ambulatory Care segment, at $1.388 billion, is the key growth driver as Tenet continues to shift its mix toward higher-margin outpatient services, while Hospital Operations at $4.24 billion remains the revenue backbone. This steady mid-single-digit growth, combined with raised full-year guidance, supports the investment case for a company transitioning from a leveraged hospital operator to a diversified, cash-generative care platform.
Profitability has improved markedly, with Q2 2026 net income of $826 million translating to a net margin of 14.68%, up from 5.46% in Q2 2025 and 6.47% in Q3 2025. The company's gross margin of 82.26% (on a trailing basis per the valuation data) reflects the service-oriented nature of healthcare delivery, though the quarterly income statement shows a gross profit ratio of 18.19% when cost of revenue is defined more broadly to include operating expenses. EBITDA has been robust, reaching $1.239 billion in Q2 2026 with an EBITDA margin of 22.01%, and operating income of $1.024 billion represents an 18.19% operating margin. The company's ROE of 33.34% is exceptionally strong for the healthcare facilities industry, reflecting both operational efficiency and the leverage inherent in the capital structure, while the ROA of 8.32% indicates productive asset utilization.
The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 3.12 and a total debt-to-capitalization ratio of 73.99%, which is typical for hospital operators that require heavy capital investment in facilities. However, the company generates substantial free cash flow, with $3.023 billion in trailing twelve-month FCF and $417 million in Q2 2026 alone, providing ample coverage for its $168 million in quarterly capital expenditures. The current ratio of 1.76 and quick ratio of 1.35 indicate adequate short-term liquidity, while the interest coverage ratio of 5.02x provides a comfortable cushion for debt servicing. The company has been aggressively returning capital, repurchasing $1.042 billion in stock during Q2 2026 and $318 million in Q1 2026, funded entirely from operating cash flow of $585 million and $1.641 billion respectively, demonstrating confidence in its cash generation and commitment to shareholder returns.
Quarterly Revenue
$5.6B
2026-06
Revenue YoY Growth
+6.8%
YoY Comparison
Gross Margin
18.2%
Latest Quarter
Free Cash Flow
$3.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
With positive net income of $826 million in Q2 2026 and trailing EPS of $0.08 (reflecting the impact of the massive share count and possibly one-time items), the PE ratio is the appropriate primary metric. The trailing PE of 12.73x and forward PE of 12.26x are remarkably low for a company exhibiting 27% annual stock price appreciation and strong earnings growth, with the narrow gap between trailing and forward multiples implying the market is not pricing in dramatic near-term earnings acceleration. However, the forward PE is based on estimated EPS of $28.72, which appears inconsistent with the trailing EPS figure, suggesting the trailing EPS may be distorted by non-recurring charges or accounting nuances. The EV/EBITDA of 6.29x and price-to-sales of 0.84x further underscore the relatively modest valuation relative to the company's cash generation and revenue base.
Compared to the broader healthcare facilities industry, Tenet trades at a significant discount on most metrics, with a PS ratio of 0.84x and EV/Sales of 1.63x suggesting the market values each dollar of revenue at a fraction of what many peers command. The price-to-book ratio of 4.25x is elevated relative to the low PS ratio, reflecting the company's negative or thin tangible book value due to years of leverage and buybacks. The PEG ratio of -0.24 is not meaningful given the negative earnings growth rate implied by the calculation, but the forward PE of 12.26x against estimated EPS growth suggests a compelling value proposition if the company can sustain its earnings trajectory. The premium on book value is justified by the company's 33.34% ROE, which far exceeds the cost of equity and indicates that retained earnings are being deployed productively.
Historically, Tenet's PE ratio has ranged from a low of 1.21x in Q1 2024 (distorted by a one-time gain) to a high of 37.54x in Q2 2022, with the current 12.73x sitting in the lower-middle portion of that range. The PS ratio of 0.84x is near the low end of its historical band, which has ranged from roughly 1.02x to 3.38x over the past several years, suggesting the stock is inexpensive relative to its own revenue multiple history. The price-to-free-cash-flow ratio of 5.06x is exceptionally low, indicating the market is pricing in significant skepticism about the sustainability of current cash flows or is undervaluing the company's capital-return potential. This historical context suggests either a compelling value opportunity or a market that is discounting future headwinds such as reimbursement pressure or volume declines.
PE
12.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Tenet Healthcare carries substantial financial and operational risks, primarily stemming from its high leverage. The debt-to-equity ratio of 3.12 and total debt-to-capitalization of 73.99% indicate a heavily indebted balance sheet, with quarterly interest expense of $204 million consuming a significant portion of operating income. While the interest coverage ratio of 5.02x provides a cushion, any decline in EBITDA could quickly erode this buffer. Additionally, the company's revenue is concentrated in hospital operations ($4.24 billion in Q2 2026), which are vulnerable to changes in reimbursement rates and patient volumes. The recent Q1 2026 revenue miss due to unfavorable payer mix underscores this risk, and if such issues persist, margins could compress.
Market and competitive risks are also prominent. The stock trades at a premium price-to-book ratio of 4.25x, which may not be justified if growth slows. The healthcare sector faces regulatory headwinds, including potential changes to Medicare and Medicaid reimbursement, which could impact profitability. With a beta of 1.23, the stock is more volatile than the market, and sector rotation could lead to underperformance. Recent news highlights the company's reliance on cash flow to support its capital-return strategy, but any deterioration in cash generation could force a reduction in buybacks, removing a key support for the stock price. Competition from other healthcare providers and alternative care settings could also pressure volumes.
The worst-case scenario for Tenet involves a combination of declining patient volumes, unfavorable payer mix, and rising interest rates, leading to margin compression and reduced cash flow. This could trigger a sell-off, with the stock potentially falling to its 52-week low of $157.58, representing a 39% decline from the current price of $258.62. The analyst low target of $260 offers little downside protection, but in a severe downturn, the stock could test the low end of its historical valuation range. Given the maximum drawdown of -34.08% over the past year, investors should be prepared for significant volatility and potential losses in adverse conditions.
FAQ
The key risks include: 1) Financial risk from high leverage (debt-to-equity of 3.12) and interest expense of $204 million per quarter, which could strain profitability if rates rise; 2) Operational risk from payer mix headwinds that caused a Q1 2026 revenue miss, potentially recurring; 3) Market risk due to high volatility (beta 1.23) and a maximum drawdown of -34.08% in the past year; and 4) Competitive risk from alternative care settings and regulatory changes. These risks could lead to significant downside, with the 52-week low at $157.58 representing a 39% decline from current levels.
The 12-month forecast is based on three scenarios: bull case (30% probability) targets $300-$315, driven by successful ambulatory expansion and multiple expansion; base case (50% probability) targets $270-$290, assuming steady growth and stable margins; and bear case (20% probability) targets $157.58-$230, triggered by payer mix issues and margin compression. The base case is most likely, with the stock expected to reach the analyst average target of $284.64. Key assumptions include revenue growth of 6.5% and net margin holding at 14%.
THC appears undervalued based on most metrics. Its trailing PE of 12.73x and forward PE of 12.26x are below the broader market and its historical average. The PS ratio of 0.84x is near the low end of its historical range (1.02x-3.38x), and EV/EBITDA of 6.29x is attractive. However, the price-to-book ratio of 4.25x is elevated due to thin tangible book value. The market may be discounting future headwinds such as reimbursement pressure, but the low multiples suggest a value opportunity if growth persists.
Tenet Healthcare appears to be a good buy for value-oriented investors, given its low forward PE of 12.26x and strong free cash flow yield. The analyst consensus target of $284.64 implies 10.1% upside, and the company's aggressive buybacks support EPS growth. However, the high debt-to-equity ratio of 3.12 and recent revenue miss due to payer mix are notable risks. It is most suitable for investors with a medium risk tolerance and a 1-2 year horizon, who can withstand volatility (beta 1.23).
THC is more suitable for medium- to long-term investment (1-3 years) rather than short-term trading, given its volatility (beta 1.23) and the time needed for its strategic initiatives to fully materialize. The company does not pay dividends, so returns depend on capital appreciation. Short-term traders might exploit momentum, but the recent deceleration (1-month gain of 3.48%) suggests choppy trading. A minimum holding period of 12-18 months is recommended to ride out potential drawdowns and benefit from earnings growth and buybacks.